ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc. and IMGN151, an anti FRa product candidate. The company has collaborations with Roche Amgen/Oxford BioTherapeutics Bayer HealthCare AG Eli Lilly and Company Novartis Institutes for BioMedical Research, Inc. CytomX Therapeutics, Inc. Fusion Pharmaceuticals Inc. Debiopharm International SA and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.